AstriVax aims for initial clinical validation of the platform technology, to develop a broad vaccination pipeline.
AstriVax has raised $3.2M in total funding. The most recent round was Grant. The last funding was announced in December 2023.
AstriVax's investors include Mérieux Equity Partners, V-Bio Ventures, Thuja Capital, Gemma Frisius Fund, Fund+.
AstriVax is headquartered in Heverlee, Belgium.
AstriVax aims for initial clinical validation of the platform technology, to develop a broad vaccination pipeline.
AstriVax is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"AstriVax — Funding & Investors." VCBacked, December 12, 2023, https://www.vcbacked.co/company/astrivax. Accessed August 14, 2026.
VCBacked. (2023). AstriVax — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/astrivax
{{cite web |title=AstriVax — Funding & Investors |url=https://www.vcbacked.co/company/astrivax |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated